The stock of Monte Rosa Therapeutics Inc. (NASDAQ:GLUE) increased by $0.01 on Friday to finish at $6.69, up 0.15 percent. The last five days have seen an average of 185,900 shares of common stock traded. 3 times new highs were reached in the current year, with a fall of -$0.92. The average number of shares traded over the last 20 days was 110,300, while the average volume over the last 50 days totaled 148,306.
GLUE stock dropped -6.69% since last month. On 08/11/23, the company’s shares reached a one-month low of $6.50. The stock touched a high of $10.96 on 06/16/23, after rallying from a low of $4.40 in 52 weeks. The price of GLUE stock has declined by -12.09% or -$0.92 this year, reaching a new high 3 times. Still, the stock price is down -38.96% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Financial Health
For the three months ended June 29, Monte Rosa Therapeutics Inc.’s quick ratio was 10.90, while its current ratio was 10.90, indicating its ability to pay off its debt.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. GLUE’s return on assets (ROA) during the last 12 months has been -38.90%. In the meantime, the return on equity (ROE) for the last 12 months was -49.10%.
Earnings Surprise
According to Monte Rosa Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29, it had $156.04 million in cash and short-term investments. A higher net income was reported in the quarter under review than the previous quarter. It was predicted that Monte Rosa Therapeutics Inc.’s quarterly earnings would be -$0.71, but it ended up being -$0.7, beating the consensus by -1.40%. EBITDA was -$35.83 million for the quarter. At the end of Monte Rosa Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 64.96 million, while its total debt was $47.03 million. Equity owned by shareholders amounts to $49.66 million.
Technical Picture
Here’s a quick look at Monte Rosa Therapeutics Inc.’s (GLUE) price momentum from a technical perspective. As of 11 August, the RSI 9-day stood at 42.87%, suggesting the stock is Neutral, with a 26.73% historical volatility rate.
The stochastic %K and %D were 25.92% and 29.53% respectively, while the average true range (ATR) was 0.40. Based on the 14-day stochastic reading of 22.89%, the RSI (14) reading is 45.84%. On the 9-day MACD Oscillator, the stock is at -0.06, and the 14-day reading is at -0.10.
Analyst Ratings
In its most recent analyst report, Wells Fargo raised its rating on Monte Rosa Therapeutics Inc. (NASDAQ: GLUE) to an Overweight. Prior to this, analysts firm rated the stock as an Equal weight. Analysts have assigned Monte Rosa Therapeutics Inc. (GLUE) an Buy rating. GLUE is a stock that is recommended for selling by 0 brokerage firms, while 2 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 8 others recommend it as a buy.
What is GLUE’s price target for the next 12 months?
The current consensus forecast for the stock is between $11.00 and $31.00, with a median target price of $21.00. In analyzing these forecasts, the average price target given by analysts for Monte Rosa Therapeutics Inc. (GLUE) is $20.89.
